RxDoctor Payments Data

Elissa Thompson, MD

Cardiovascular Disease · Hyannis, MANPI 1710157615

Payments from drug & device makers

$195in general payments, 2019–2025

Across 10 payments — averaging $19.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$50
  • E.r. Squibb & Sons, L.L.C.$45
  • Abbott$25
  • Heartflow, Inc.$22
  • Novartis$22
  • Amarin Pharma, Inc.$18
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$195100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$195 in reported general payments places this provider in the 25th percentile of 750 cardiovascular disease providers in Massachusetts.

See all cardiovascular disease providers in Massachusetts

Medicare billing

Part B allowed, 2024
$409,902
Medicare patients
2,129
Services billed
6,614

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban444$627,835
XareltoRivaroxaban273$393,513
FarxigaDapagliflozin Propanediol44$36,671
JardianceEmpagliflozin24$29,659
Atorvastatin Calcium1,518$24,415
Metoprolol Succinate995$20,135
Rosuvastatin Calcium447$14,011
Ezetimibe177$8,925
VascepaIcosapent Ethyl11$8,235
Dabigatran EtexilateDabigatran Etexilate Mesylate15$6,290
BrilintaTicagrelor13$5,769
Losartan Potassium213$2,985
Diltiazem 24hr Er (Cd)Diltiazem Hcl87$2,648
Lisinopril366$2,419
ClopidogrelClopidogrel Bisulfate112$2,283

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$13$42,44057 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 750 cardiovascular disease providers in Massachusetts.

Other cardiovascular disease in Hyannis

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →